Xinjiang Bai Hua Cun Pharma Tech (600721.SH) reported a forecasted increase, with an estimated net profit of 36 to 46 million yuan for the year 2024, representing a year-on-year increase of 177.56% to 254.66%.

Xinjiang Bai Hua Cun Pharma Tech (600721.SH) announced that the company expects to achieve a net profit attributable to shareholders of the listed company of 36 million to 46 million yuan in 2024, an increase of 23.03 million to 33.03 million yuan compared to the same period last year, representing a year-on-year increase of 177.56% to 254.66%. During the reporting period, the company intensified market promotion, enhanced technical capabilities, improved research and development efficiency, shortened project delivery cycles, strengthened cost control, and achieved significant profit growth through increased operating income, reduced project research and development costs, and increased gross profit.